Compare Altria Group Inc (MO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs TG Therapeutics Inc — how do they compare? Altria Group Inc trades at $64.45 (market cap $108.58B), while TG Therapeutics Inc trades at $49.64 (market cap $7.64B). The key difference: Altria Group Inc is far larger — about 14.2× TG Therapeutics Inc's market cap, and Altria Group Inc pays a 6.52% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MO | TGTX | |
|---|---|---|
Market Cap | $108.58B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $59.06 |
52-Week Low | $54.72 | $26.94 |
Enterprise Value | $130.79B | $7.84B |
Dividend Yield | 6.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $64.83, down 1.08% on the day, with a bearish technical signal but strong fundamentals including a 39% net income margin and a P/E of 13.69. Recent earnings showed mixed results, with Q1 2026 beating expectations but Q2 missing. The company maintains robust cash flow from operations of $9.29 billion in 2025 and a dividend yield of approximately 6.3%, with a payout scheduled for July 2026. Analyst consensus is bullish with a $67 price target, though legal investigations and cigarette volume declines pose headwinds.
Outlook: MO offers value through dividends and stable cash flows, but faces risks from regulatory pressures and declining smokable product demand. Investment opportunity lies in its smoke-free transition and pricing power, yet investors must weigh litigation risks and market sentiment shifts. Near-term price movement may hinge on Q3 2026 earnings and dividend announcements.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
